Literature DB >> 15689149

Structure of human cytidine deaminase bound to a potent inhibitor.

Sang J Chung1, J Christopher Fromme, Gregory L Verdine.   

Abstract

Human cytidine deaminase (CDA) is an enzyme prominent for its role in catalyzing metabolic processing of nucleoside-type anticancer and antiviral agents. It is thus a promising target for the development of small molecule therapeutic adjuvants. We report the first crystal structure of human CDA as a complex with a tight-binding inhibitor, diazepinone riboside 1. The structure reveals that inhibitor 1 is able to establish a canonical pi/pi-interaction with a key active site residue, Phe 137.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15689149     DOI: 10.1021/jm0496279

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

Review 1.  The current structural and functional understanding of APOBEC deaminases.

Authors:  Ronda Bransteitter; Courtney Prochnow; Xiaojiang S Chen
Journal:  Cell Mol Life Sci       Date:  2009-06-23       Impact factor: 9.261

Review 2.  The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?

Authors:  Audrey Frances; Pierre Cordelier
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

3.  Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells.

Authors:  Hongmei Ruan; Songbo Qiu; Brian C Beard; Margaret E Black
Journal:  Protein Eng Des Sel       Date:  2016-05-08       Impact factor: 1.650

4.  Contrasting behavior of conformationally locked carbocyclic nucleosides of adenosine and cytidine as substrates for deaminases.

Authors:  Victor E Marquez; Gottfried K Schroeder; Olaf R Ludek; Maqbool A Siddiqui; Abdallah Ezzitouni; Richard Wolfenden
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2009-05       Impact factor: 1.381

5.  Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces.

Authors:  Shivender M D Shandilya; Madhavi N L Nalam; Ellen A Nalivaika; Phillip J Gross; Johnathan C Valesano; Keisuke Shindo; Ming Li; Mary Munson; William E Royer; Elena Harjes; Takahide Kono; Hiroshi Matsuo; Reuben S Harris; Mohan Somasundaran; Celia A Schiffer
Journal:  Structure       Date:  2010-01-13       Impact factor: 5.006

6.  Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits.

Authors:  Joseph E Wedekind; Richard Gillilan; Alena Janda; Jolanta Krucinska; Jason D Salter; Ryan P Bennett; Jay Raina; Harold C Smith
Journal:  J Biol Chem       Date:  2006-10-31       Impact factor: 5.157

7.  1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure.

Authors:  Nadine M Shaban; Ke Shi; Ming Li; Hideki Aihara; Reuben S Harris
Journal:  J Mol Biol       Date:  2016-04-30       Impact factor: 5.469

8.  Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications.

Authors:  Lauren G Holden; Courtney Prochnow; Y Paul Chang; Ronda Bransteitter; Linda Chelico; Udayaditya Sen; Raymond C Stevens; Myron F Goodman; Xiaojiang S Chen
Journal:  Nature       Date:  2008-10-12       Impact factor: 49.962

9.  New Frontiers in Druggability.

Authors:  Dima Kozakov; David R Hall; Raeanne L Napoleon; Christine Yueh; Adrian Whitty; Sandor Vajda
Journal:  J Med Chem       Date:  2015-08-11       Impact factor: 7.446

10.  Synthesis and conformational analysis of locked carbocyclic analogues of 1,3-diazepinone riboside, a high-affinity cytidine deaminase inhibitor.

Authors:  Olaf R Ludek; Gottfried K Schroeder; Chenzhong Liao; Pamela L Russ; Richard Wolfenden; Victor E Marquez
Journal:  J Org Chem       Date:  2009-08-21       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.